Aramed Inc., Gensia Inc. deal

GNSA determined the exchange ratio for the number of GNSA shares each ARAM shareholder would receive under GNSA's proposed acquisition of the R&D financing unit (see BioCentury June 19).

In addition, ARAM shareholders would receive a right maturing on Dec. 31, 1996, to potentially receive up to an additional 0.75 of a share of GNSA common stock for each ARAM share. If the price of GNSA common equals or exceeds $4.50 per share for 20 consecutive days between issuance and maturity, the right would be reduced to 0.375 of a GNSA share. The December right will expire if GNSA's price equals or exceeds $5.25 for 20 consecutive trading days. ...